Alan Cowman

Nanobodies against Pfs230 block Plasmodium falciparum transmission.

Dietrich MH, Gabriela M, Reaksudsan K, Dixon MWA, Chan LJ, Adair A, Trickey S, O'Neill MT, Tan LL, Lopaticki S, Healer J, Keremane S, Cowman AF, Tham WH.

Biochem J. 2022 12 22. 479(24):2529-2546. PMID: 36520108

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

Healer J, Thompson JK, Mackwell KL, Browne CD, Seager BA, Ngo A, Lowes KN, Silk SE, Pulido D, King LDW, Christen JM, Noe AR, Kotraiah V, Masendycz PJ, Rajagopalan R, Lucas L, Stanford MM, Soisson L, Diggs C, Miller R, Youll S, Wycherley K, Draper SJ, Cowman AF.

Front Cell Infect Microbiol. 2022. 12:1049065. PMID: 36605129

PCRCR complex is essential for invasion of human erythrocytes by Plasmodium falciparum.

Scally SW, Triglia T, Evelyn C, Seager BA, Pasternak M, Lim PS, Healer J, Geoghegan ND, Adair A, Tham WH, Dagley LF, Rogers KL, Cowman AF.

Nat Microbiol. 2022 12. 7(12):2039-2053. PMID: 36396942

The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.

de Lera Ruiz M, Favuzza P, Guo Z, Zhao L, Hu B, Lei Z, Zhan D, Murgolo N, Boyce CW, Vavrek M, Thompson J, Ngo A, Jarman KE, Robbins J, Boddey J, Sleebs BE, Lowes KN, Cowman AF, Olsen DB, McCauley JA.

ACS Med Chem Lett. 2022 Nov 10. 13(11):1745-1754. PMID: 36385924

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362.

Lowe MA, Cardenas A, Valentin JP, Zhu Z, Abendroth J, Castro JL, Class R, Delaunois A, Fleurance R, Gerets H, Gryshkova V, King L, Lorimer DD, MacCoss M, Rowley JH, Rosseels ML, Royer L, Taylor RD, Wong M, Zaccheo O, Chavan VP, Ghule GA, Tapkir BK, Burrows JN, Duffey M, Rottmann M, Wittlin S, Angulo-Barturen I, Jiménez-Díaz MB, Striepen J, Fairhurst KJ, Yeo T, Fidock DA, Cowman AF, Favuzza P, Crespo-Fernandez B, Gamo FJ, Goldberg DE, Soldati-Favre D, Laleu B, de Haro T.

J Med Chem. 2022 10 27. 65(20):14121-14143. PMID: 36216349

Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.

Richardson LW, Ashton TD, Dans MG, Nguyen N, Favuzza P, Triglia T, Hodder AN, Ngo A, Jarman KE, Cowman AF, Sleebs BE.

ChemMedChem. 2022 09 16. 17(18):e202200306. PMID: 35906744

The Plasmodium falciparum parasitophorous vacuole protein P113 interacts with the parasite protein export machinery and maintains normal vacuole architecture.

Bullen HE, Sanders PR, Dans MG, Jonsdottir TK, Riglar DT, Looker O, Palmer CS, Kouskousis B, Charnaud SC, Triglia T, Gabriela M, Parkyn Schneider M, Chan JA, de Koning-Ward TF, Baum J, Kazura JW, Beeson JG, Cowman AF, Gilson PR, Crabb BS.

Mol Microbiol. 2022 05. 117(5):1245-1262. PMID: 35403274

Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.

Hodder AN, Christensen J, Scally S, Triglia T, Ngo A, Birkinshaw RW, Bailey B, Favuzza P, Dietrich MH, Tham WH, Czabotar PE, Lowes K, Guo Z, Murgolo N, Lera Ruiz M, McCauley JA, Sleebs BE, Olsen D, Cowman AF.

Structure. 2022 07 07. 30(7):947-961.e6. PMID: 35460613

RhopH2 and RhopH3 export enables assembly of the RhopH complex on P. falciparum-infected erythrocyte membranes.

Pasternak M, Verhoef JMJ, Wong W, Triglia T, Mlodzianoski MJ, Geoghegan N, Evelyn C, Wardak AZ, Rogers K, Cowman AF.

Commun Biol. 2022 04 07. 5(1):333. PMID: 35393572

Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria.

Studniberg SI, Ioannidis LJ, Utami RAS, Trianty L, Liao Y, Abeysekera W, Li-Wai-Suen CSN, Pietrzak HM, Healer J, Puspitasari AM, Apriyanti D, Coutrier F, Poespoprodjo JR, Kenangalem E, Andries B, Prayoga P, Sariyanti N, Smyth GK, Cowman AF, Price RN, Noviyanti R, Shi W, Garnham AL, Hansen DS.

Mol Syst Biol. 2022 04. 18(4):e10824. PMID: 35475529